keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28805018/pain-catastrophizing-is-strongly-associated-with-subjective-outcomes-but-not-with-inflammatory-assessments-in-rheumatoid-arthritis-patients
#1
Hilde B Hammer, Till Uhlig, Tore K Kvien, Jon Lampa
OBJECTIVES: Pain catastrophizing is conceptualized as a negative cognitive-affective response to anticipated or actual pain and has been associated with important pain-related outcomes. The objective of this prospective study of established rheumatoid arthritis (RA) patients was to explore how pain catastrophizing was related to patient-reported outcomes (PROs), composite scores and assessments of inflammatory activity. METHODS: RA patients starting bDMARD were examined at baseline and after 1, 2, 3, 6 and 12 months with PROs (joint pain/patient's global VAS, MHAQ, RAID score), clinical and laboratory assessments (tender/swollen joint count, assessor's global VAS, ESR/CRP), ultrasound (US) (grey scale/power Doppler of 36 joints and 4 tendons) and pain catastrophizing...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28794381/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-after-six-months-of-non-tumor-necrosis-factor-biological-disease-modifying-antirheumatic-drugs-dmards-treatment
#2
Yusuke Miwa, Mayu Saito, Hidekazu Furuya, Ryo Yanai, Yuzo Ikari, Tomoki Hayashi, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki
Objectives We aimed to identify the factors that predict the likelihood of remission based on a health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients who received non-tumor necrosis factor (TNF) biologics for six months before they commenced definitive treatment. Methods The subjects consisted of 97 RA patients treated with tocilizumab or abatacept for 6 months. The following characteristics were investigated: age, gender, body mass index, steroid and methotrexate dosage, serum matrix metalloproteinase-3 levels, simplified disease activity index (SDAI) score, HAQ score (for assessing the activities of daily living [ADL]) and the short form (SF)-36 score (for assessing the quality of life [QOL])...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28791286/autoimmune-thrombotic-thrombocytopenic-purpura-two-rare-cases-associated-with-juvenile-idiopathic-arthritis-and-multiple-sclerosis
#3
Despoina Dimopoulou, Athina Dimosiari, Eudokia Mandala, Theodoros Dimitroulas, Alaxandros Garyfallos
Secondary thrombotic microangiopathies are associated with several underlying conditions, with most of them being resolved after the treatment of background disease. Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathy presenting with anemia, thrombocytopenia, and neurological deficits, occurring most often in various autoimmune diseases due to inhibition of ADAMTS13 by autoantibodies, as well as in pregnant women with or without an autoimmune substrate. In this article, we report two newly diagnosed TTP cases, who have not been published so far...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28790870/repository-corticotropin-injection-as-adjunctive-therapy-in-patients-with-rheumatoid-arthritis-who-have-failed-previous-therapies-with-at-least-three-different-modes-of-action
#4
Theresa Gillis, Megan Crane, Carly Hinkle, Nathan Wei
OBJECTIVE: Many types of treatment are available for patients with rheumatoid arthritis (RA), however, some patients fail to achieve remission. This report aims to determine the safety and efficacy of using repository corticotropin injection (RCI) as an adjunctive therapy in patients with RA refractory to at least three therapeutics with different mechanisms of action. METHOD: In this open-label, interventional, single-group study, patients received 80 U RCI twice weekly via subcutaneous injection over 12 weeks...
2017: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/28790869/etanercept-enbrel-%C3%A2-alternative-storage-at-ambient-temperature
#5
Edel Shannon, Joanne Daffy, Heather Jones, Andrea Paulson, Steven M Vicik
BACKGROUND: Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors such as etanercept (Enbrel(®)), have improved outcomes for patients with rheumatic and other inflammatory diseases, with sustained remission being the optimal goal for patients with rheumatoid arthritis. Flexible and convenient treatment options, compatible with modern lifestyle, are important in helping patients maintain treatment and manage their disease. Etanercept drug product (DP) is available in lyophilized powder (Lyo) for solution injection, prefilled syringe, and prefilled pen presentations and is typically stored under refrigerated conditions...
2017: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/28789978/a-composite-indicator-to-assess-the-quality-of-care-in-the-management-of-patients-with-rheumatoid-arthritis-in-outpatient-rheumatology-clinics
#6
María Auxiliadora Martín-Martínez, Jose Luis Andreu-Sanchez, Fernando Sanchez-Alonso, Hector Corominas, Jose Javier Perez-Venegas, Jose Andres Roman-Ivorra, Mercedes Alperi, Ricardo Blanco-Alonso, Rafael Caliz, Eugenio Chamizo-Carmona, Jenaro Graña-Gil, Blanca Hernández, Carlos Marras, Ramon Mazzucchelli, Julio Antonio Medina Luezas, Antonio Naranjo-Hernández, Ana Ortiz, Rosa Roselló, Ginés Sanchez-Nievas, Raimon Sanmartí, Paloma Vela-Casasempere
OBJECTIVE: The current guidelines in the treatment of rheumatoid arthritis (RA) include the early diagnosis and early use of disease modifying drugs to achieve remission or low disease activity level, known as "Treat to Target" (T2T). The objective of this study is to develop a composite indicator (CI) to evaluate the quality of care in the management of patients with RA, according to the T2T strategy and other general recommendations concerning the management of these patients. MATERIAL AND METHOD: The phases of the construction of the CI were: 1) selection of quality criteria through expert judgment; 2) prioritization of the criteria, according to relevance and feasibility, applying the Delphi methodology (two rounds) involving 20 experts; 3) design of quality indicators; and 4) calculation of the weighted CI, using the mean value in relevance and feasibility granted by the experts...
August 5, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28774458/ultrasound-in-arthritis
#7
REVIEW
Iwona Sudoł-Szopińska, Claudia Schueller-Weidekamm, Athena Plagou, James Teh
Ultrasound is currently performed in everyday rheumatologic practice. It is used for early diagnosis, to monitor treatment results, and to diagnose remission. The spectrum of pathologies seen in arthritis with ultrasound includes early inflammatory features and associated complications. This article discusses the spectrum of ultrasound features of arthritides seen in rheumatoid arthritis and other connective tissue diseases in adults, such as Sjögren syndrome, lupus erythematosus, dermatomyositis, polymyositis, and juvenile idiopathic arthritis...
September 2017: Radiologic Clinics of North America
https://www.readbyqxmd.com/read/28772079/biological-anti-tnf-drugs-immunogenicity-underlying-treatment-failure-and-adverse-events
#8
Mônica Simon Prado, Klaus Bendtzen, Luis Eduardo Coelho Andrade
Genetically engineered monoclonal antibodies and fusion proteins directed against cytokines or their receptors represent a breakthrough in the treatment of various chronic immune-inflammatory diseases. Areas Covered: Studies show high remission rates in several diseases, but clinical practice shows a significant percentage of individuals who do not exhibit the desired response. Loss of therapeutic benefit after initial successful response is designated secondary failure. Immune-biological agents are not self-antigens and are therefore potentially immunogenic...
August 3, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28768630/back-to-the-future-forget-ultrasound-and-focus-on-clinical-assessment-in-rheumatoid-arthritis-management
#9
EDITORIAL
Roberto Caporali, Josef S Smolen
Ultrasound (US) unquestionably improves many aspects of rheumatoid arthritis (RA) diagnosis and management, but no consensus has been reached regarding the optimal US methodology that should be used, and high levels of standardisation have not yet been attained. Current evidence from two randomised controlled trials does not support the US in directing treatment decisions. A return to the endorsement of clinical assessment and the adoption of T2T strategies aiming at ACR/EULAR remission still represent the standard of care for RA and should be pursued through appropriate educational programmes...
August 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28765250/validating-rheumatoid-arthritis-remission-using-the-patients-perspective-results-from-a-special-interest-group-at-omeract-2016
#10
Linda A Rasch, Maarten Boers, Catherine L Hill, Marieke Voshaar, Wijnanda Hoogland, Maarten de Wit, Caroline Flurey, Bev Davis, Merete Lund Hetland, Cecilie Heegaard Brahe, Laure Gossec, George A Wells, Peter Tugwell, Bindee Kuriya, Niti Goel, Jasvinder A Singh, Cátia Duarte, José Da Silva, Dirkjan van Schaardenburg, Susanna Proudman, Lilian H D van Tuyl
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) working group on the patients' perspective on remission in rheumatoid arthritis (RA) has been working on this topic since 2010. At OMERACT 2016, progress and preliminary data on validity of measurement instruments for pain, fatigue, and independence in remission in RA were presented, and future directions were explored. METHODS: A special interest group was organized, in which the current data on the patients' perspective on remission were presented...
August 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28757342/rheumatoid-arthritis-treated-with-tocilizumab-in-two-patients-with-complicated-chronic-liver-disease-with-portal-hypertension
#11
Adamah Amouzougan, Delphine Dénarié, Hubert Marotte, Xavier Roblin, Thierry Thomas
Erosive, active rheumatoid arthritis in patients with portal hypertension combining esophageal varices and ascites complicating chronic liver disease poses serious management problems. Current literature does not provide any valid therapeutic management. We report the case of a woman and a man aged 52 and 66 years respectively having this combination of pathologies. Infusions of 4mg/kg of tocilizumab as monotherapy have produced a weaning from corticosteroids, both clinical and structural remission, with particular liver safety satisfactory at 10 and 18 months...
July 27, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28756532/etanercept-is-effective-as-monotherapy-or-in-combination-with-methotrexate-in-rheumatoid-arthritis-subanalysis-of-an-observational-study
#12
Markus Gaubitz, Karl-Heinz Göttl, Olaf Behmer, Ralph Lippe, Thomas Meng, Peter-Andreas Löschmann
Approximately 30% of patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs (bDMARDs) take them as monotherapy. Although etanercept (ETN) monotherapy has been evaluated in clinical trials, data in the real-world setting are sparse. We compared the efficacy and safety of ETN, given alone or in combination with methotrexate (MTX), in routine clinical practice. This was a subanalysis of patients who received either ETN alone or ETN + MTX during a 52-week prospective, observational study conducted at 329 German centers...
July 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28737837/drug-survival-and-reasons-for-discontinuation-of-the-first-biological-disease-modifying-antirheumatic-drugs-in-thai-patients-with-rheumatoid-arthritis-analysis-from-the-thai-rheumatic-disease-prior-authorization-registry
#13
Pongthorn Narongroeknawin, Parawee Chevaisrakul, Nuntana Kasitanon, Tasanee Kitumnuaypong, Ajanee Mahakkanukrauh, Boonjing Siripaitoon, Wanruchada Katchamart
AIM: To evaluate and compare the retention rate of biological disease-modifying antirheumatic drugs (bDMARDs) in real-life practice and identify risk factors related to remission and drug discontinuation in patients with rheumatoid arthritis (RA). METHOD: A total of 256 patients fulfilling criteria for RA and starting bDMARD between December 2009 and October 2014 were selected from the Rheumatic Disease Prior Authorization registry. Baseline demographic and clinical data were recorded...
November 5, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28733473/do-depression-and-anxiety-reduce-the-likelihood-of-remission-in-rheumatoid-arthritis-and-psoriatic-arthritis-data-from-the-prospective-multicentre-nor-dmard-study
#14
Brigitte Michelsen, Eirik Klami Kristianslund, Joseph Sexton, Hilde Berner Hammer, Karen Minde Fagerli, Elisabeth Lie, Ada Wierød, Synøve Kalstad, Erik Rødevand, Frode Krøll, Glenn Haugeberg, Tore K Kvien
OBJECTIVE: To investigate the predictive value of baseline depression/anxiety on the likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as the associations between baseline depression/anxiety and the components of the remission criteria at follow-up. METHODS: We included 1326 patients with RA and 728 patients with PsA from the prospective observational NOR-DMARD study starting first-time tumour necrosis factor inhibitors or methotrexate...
July 21, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28730687/efficacy-of-abatacept-in-patients-with-rheumatoid-arthritis-as-assessed-by-magnetic-resonance-imaging-of-bilateral-hands
#15
Yuji Kukida, Akiko Kasahara, Takahiro Seno, Takuya Inoue, Risa Sagawa, Takashi Kida, Amane Nakabayashi, Hidetake Nagahara, Ken Murakami, Toshifumi Sugitani, Satoshi Morita, Hirotoshi Ito, Ryo Oda, Hiroyoshi Fujiwara, Masataka Kohno, Yutaka Kawahito
AIM: To examine the efficacy of abatacept in patients with rheumatoid arthritis (RA) using magnetic resonance imaging (MRI) of bilateral hands. METHOD: This prospective study included 35 RA patients. MRI of bilateral hands was performed at baseline and after 12 months of treatment with intravenous abatacept. MRI images were scored for synovitis, osteitis, erosion and joint space narrowing (JSN) according to the RA MRI Scoring System (RAMRIS). The primary endpoint was the change in RAMRIS score from baseline...
July 21, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28728565/identification-of-differential-co-expressed-gene-networks-in-early-rheumatoid-arthritis-achieving-sustained-drug-free-remission-after-treatment-with-a-tocilizumab-based-or-methotrexate-based-strategy
#16
Xavier M Teitsma, Johannes W G Jacobs, Michal Mokry, Michelle E A Borm, Attila Pethö-Schramm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J Lafeber
BACKGROUND: Methotrexate is endorsed to be used as first-line treatment in rheumatoid arthritis (RA). However, a large proportion of patients need additional treatment with a biological disease-modifying anti-rheumatic drug (DMARD) to adequately suppress their disease activity. A better understanding of genotypes could help to distinguish between patients with different pathogenic mechanisms. The aim of this study was therefore to identify networks of genes within DMARD-naive early RA patients associated with achieving sustained drug-free remission (sDFR) after initiating tocilizumab plus methotrexate, tocilizumab, or methotrexate therapy...
July 20, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28726020/patterns-of-circulatory-and-peripheral-blood-mononuclear-cytokines-in-rheumatoid-arthritis
#17
Fawaz Y Azizieh, Khaled Al Jarallah, Diaa Shehab, Renu Gupta, Kamaludin Dingle, Raj Raghupathy
An imbalance in pro- and anti-inflammatory cytokines is suggested to contribute to tissue damage in rheumatoid arthritis (RA). This study was aimed at investigating profiles of cytokines in circulation and cytokines produced by mitogen-stimulated peripheral blood mononuclear cells (PBMC) in RA patients and healthy controls, and to explore correlations of cytokines with disease activity. Our aim was to identify patterns of cytokine expression as possible indicators of disease activity. Levels of plasma cytokines and PBMC-secreted cytokines were estimated in 26 female RA patients and 28 controls...
July 19, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28725981/certolizumab-pegol-was-effective-for-treating-residual-synovitis-after-total-knee-arthroplasty-in-a-patient-with-rheumatoid-arthritis-therapeutic-monitoring-by-ultrasound
#18
Shin-Ya Kawashiri, Tohru Michitsuji, Atsushi Kawakami
We present the case of a 59-year-old female who developed rheumatoid arthritis in 2007. Right total knee arthroplasty (TKA) was performed in 2008. Although she was treated with methotrexate (MTX) after the operation, this treatment was insufficient. Infliximab (IFX) was introduced in 2001, and she achieved clinical remission. Left TKA was performed in October 2014. Because active synovitis was not detected by ultrasound after the operation, IFX was discontinued. She had been treated with MTX 8 mg weekly. However, arthralgia of the bilateral knees developed in March 2015...
July 19, 2017: Journal of Medical Ultrasonics
https://www.readbyqxmd.com/read/28725502/universal-2-wrist-arthroplasty-in-rheumatoid-arthritis
#19
Sandra Pfanner, Giovanni Munz, Giulia Guidi, Massimo Ceruso
Purpose  The aim of this study was to evaluate the mid- to long-term outcomes and complications in patients affected by rheumatic diseases treated with the Universal 2 (U2) total wrist arthroplasty (TWA). Methods  We reviewed, in a retrospective, noncontrolled cohort study, 22 patients affected by rheumatoid arthritis (RA), who underwent U2 total wrist replacement between March 2003 and January 2014 for the treatment of 23 rheumatoid wrists with the aim of obtaining the remission of pain and a range of motion (ROM) useful for daily activities, according to the patients' demands, as an alternative to total wrist arthrodesis...
August 2017: Journal of Wrist Surgery
https://www.readbyqxmd.com/read/28714991/resolution-of-inflammation-by-interleukin-9-producing-type-2-innate-lymphoid-cells
#20
Simon Rauber, Markus Luber, Stefanie Weber, Lisa Maul, Alina Soare, Thomas Wohlfahrt, Neng-Yu Lin, Katharina Dietel, Aline Bozec, Martin Herrmann, Mark H Kaplan, Benno Weigmann, Mario M Zaiss, Ursula Fearon, Douglas J Veale, Juan D Cañete, Oliver Distler, Felice Rivellese, Costantino Pitzalis, Markus F Neurath, Andrew N J McKenzie, Stefan Wirtz, Georg Schett, Jörg H W Distler, Andreas Ramming
Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (Treg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss...
August 2017: Nature Medicine
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"